Intrinsic Value of S&P & Nasdaq Contact Us

Geron Corporation GERN NASDAQ

NASDAQ Global Select • Healthcare • Biotechnology • US • USD

SharesGrow Score
55/100
4/7 Pass
SharesGrow Intrinsic Value
N/A
Negative cash flow
Analyst Price Target
$5.89
+248.5%
SharesGrow 7-Criteria Score All 7 criteria scored · valuation-related highlighted on this page

Geron Corporation (GERN) has a negative trailing P/E of -13.2, meaning the company is currently unprofitable on a trailing twelve-month (TTM) basis. The forward P/E of 59.7 based on analyst estimates suggests a return to profitability is expected. Trailing earnings yield is -7.59%, forward earnings yield 1.67%. PEG 0.33 (Peter Lynch undervalued ≤1.0).

Criteria proven by this page:

  • VALUE (88/100, Pass) — PEG ≤ 1.0 — Peter Lynch undervalued (0.33); analyst target implies upside (+248.5%).
  • Forward P/E 59.7 — analysts expect a return to profitability with estimated EPS of $0.03 for FY2027.
  • PEG Ratio 0.33 — below 1.0 suggests the stock is undervalued relative to its earnings growth rate (Peter Lynch criterion).
  • Trailing Earnings Yield -7.59% — negative yield confirms the company is currently unprofitable. Investors are paying for a turnaround rather than current earnings. Forward yield improves to 1.67% as earnings recover.
  • Analyst consensus target $5.89 (+248.5% upside) — significant upside potential according to Wall Street analysts.

Overall SharesGrow Score: 55/100 with 4/7 criteria passed.

SharesGrow 7-Criteria Score
55/100
SG Score
View full scorecard →
VALUE
88/100
Price-to-Earnings & upside
Proven by this page
FUTURE
85/100
Analyst consensus
→ Forecast
PAST
0/100
→ Income
~
HEALTH
50/100
Debt-to-Equity & liquidity
→ Health
MOAT
70/100
→ Income
GROWTH
83/100
→ Income
INCOME
10/100
→ Income

Valuation Snapshot — GERN

Valuation Multiples
P/E (TTM)-13.2
Forward P/E59.7
PEG Ratio0.33
Forward PEG0.33
P/B Ratio5.01
P/S Ratio5.90
EV/EBITDA-24.1
Per Share Data
EPS (TTM)$-0.13
Forward EPS (Est.)$0.03
Book Value / Share$0.34
Revenue / Share$0.28
FCF / Share$-0.17
Yields & Fair Value
Earnings Yield-7.59%
Forward Earnings Yield1.67%
Dividend Yield0.00%
Analyst Target$5.89 (+248.5%)

Historical Valuation

Year P/E (TTM) PEG Ratio P/B Ratio P/S Ratio Dividend Yield
2016 -11.1 0.00 2.69 53.43 -
2017 -10.3 1.95 2.76 269.11 -
2018 -6.5 0.39 0.99 165.58 -
2019 -3.8 -0.03 1.91 562.21 -
2020 -5.7 0.38 2.05 1,706.02 -
2021 -3.4 -0.11 3.16 286.94 -
2022 -6.5 0.00 11.52 1,546.14 -
2023 -6.5 0.48 4.86 5,080.43 -
2024 -13.1 0.84 8.16 29.70 -
2025 -10.3 0.20 3.90 4.79 -

EPS: Actual vs Estimates

P/E Ratio & Earnings Yield

Earnings Per Share (EPS) History

Year EPS (Diluted) Revenue Net Income Net Margin
2016 $-0.19 $6.16M $-29.54M -479.3%
2017 $-0.18 $1.07M $-27.92M -2621.2%
2018 $-0.15 $1.07M $-27.02M -2534.4%
2019 $-0.33 $460K $-63.55M -13815.4%
2020 $-0.28 $253K $-75.61M -29885.4%
2021 $-0.37 $1.39M $-120.95M -8682.8%
2022 $-0.37 $596K $-141.03M -23663.3%
2023 $-0.32 $237K $-184.13M -77690.7%
2024 $-0.27 $76.99M $-174.57M -226.7%
2025 $-0.13 $183.88M $-85.78M -46.7%

Analyst Estimates

Year EPS (Avg) EPS Range Revenue (Avg) Revenue Range Analysts
2026 $-0.04 $-0.06 – $-0.02 $229.32M $228.16M – $230.32M 3
2027 $0.03 $-0.07 – $0.11 $330.44M $301.43M – $385.35M 3
2028 $0.16 $-0.06 – $0.60 $481.38M $448.93M – $544.76M 5
2029 $0.42 $0.38 – $0.49 $687.31M $640.99M – $777.81M 1
2030 $0.64 $0.58 – $0.74 $913.65M $852.07M – $1.03B 1
Contact Us
🎓
SharesGrow Academy
Learn how to calculate Intrinsic Value and find undervalued stocks.
Weekly live sessions
Send us a message